ArticleEuropean heart journal. Cardiovascular pharmacotherapy2026

Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation.

Farheen Malik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.